Haemophilia prophylaxis: how can we justify the costs?

Haemophilia prophylaxis: how can we justify the costs?

Item
http://www.wikidata.org/entity/Q38002994
MEDICINE. Paying for future success in gene therapy.Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis.Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain.Improving haemophilia patient care through sharing best practice.EQOFIX: a combined economic and quality-of-life study of hemophilia B treatments in France.Arthroscopic partial anterior synovectomy of the knee on patients with haemophilia.An innovative outcome-based care and procurement model of hemophilia management.Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment.
P2860

Haemophilia prophylaxis: how can we justify the costs?

Item
http://www.wikidata.org/entity/Q38002994
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Haemophilia prophylaxis: how can we justify the costs?
@en
type
label
Haemophilia prophylaxis: how can we justify the costs?
@en
prefLabel
Haemophilia prophylaxis: how can we justify the costs?
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P921
P356
P1433
P1476
Haemophilia prophylaxis: how can we justify the costs?
@en
P2093
P2860
P304
P31
P356
10.1111/J.1365-2516.2012.02790.X
P433
P478
P577
P698
P921